"Ozempic and Semaglutide Unveil Surprising Life-Saving Potential, Scientists Find"

A study in Sweden suggests that GLP1 agonists like Ozempic may lower the risk of severe liver diseases such as cirrhosis and liver cancer in individuals with type 2 diabetes and chronic liver disease. The research, published in the journal Gut, found that long-term use of these drugs was associated with a reduced likelihood of developing severe liver damage. While the results need to be confirmed in clinical trials, the findings offer a potential new treatment option for preventing severe liver diseases in people with concurrent type 2 diabetes and chronic liver disease.